Neurogene Inc. (NGNE) financial statements and ratios from SEC XBRL: revenue $0.00 (latest fiscal year), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -0.9% |
| FCF Growth (YoY) | 9.7% |
| Price / Book | 3.56 |
| Price / Sales | 117.65 |
| FCF Yield | -21.2% |
| Altman Z-Score | 13.38 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
NGNE overview · NGNE earnings · NGNE KPIs · NGNE documents · NGNE ownership · NGNE peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.